JUN 24, 2017 12:10 PM PDT

Scientists Identify New Targets for Lung Cancer Immunotherapy


Our immune system has an extraordinary capacity to fight pathogens and protect the body. Indeed, some immune cells can fend off even cancer cells. Now, a recent study found that high levels of an immune T-cell can predict better outcomes for patients with lung cancer. The results could lead to immunotherapies that would enhance this body’s attack on cancer.

Image credit: Pixabay.com

Lung cancer kills more Americans than any other type of cancer. In 2016, over 224,000 people will be diagnosed with lung cancer. The disease does not discriminate between males and females, striking both sexes with equal voracity. About 70 percent of those diagnosed with lung cancer will succumb to the disease. This high mortality is contributed, in large, because the cancer is often detected at an advanced stage when treatment is not as effective.

In search of better treatment options for lung cancer patients, researchers at the University of Southampton and La Jolla Institute for Allergy & Immunology, California, turned to the immune system. When the researchers analyzed levels of immune cells in lung cancer patients, they found a striking pattern. Specifically, patients with high levels of immune cells, called tissue-resident memory T-cells, were 34 percent less likely to succumb to the cancer.

The team explored the link further, and asked how presence of these immune cells affected lung cancer growth. They found that these cells had active cancer-fighting behavior. In particular, these memory T-cells ‘took up residency’ in cancer growths and conferred protection to the body. They also triggered the production of other immune cells and molecules to help the body attack the cancer cells.

Researchers say the findings could usher in a new generation of immunotherapy-driven treatments for lung cancer patients. In particular, synthetic version of the specialized T-cells could help boost a patient's’ own immune response against the lung cancer. Or, for those who have low levels of these T-cells, the synthetic form would give their immune system a fighting chance. In addition, doctors could tailor specific therapies to patients based on the levels of their immune T-cells.

"These are hugely exciting results. For the first time we have a real indication of who might benefit from a particular drug before we make treatment decisions. So far when we use immunotherapy we do not know if a patient will benefit. The new findings are a big step towards making this exciting treatment much more predictable,” said Professor Christian Ottensmeier, Cancer Research UK scientist at the University of Southampton, and the study’s senior author.

"Our results will also make the treatment pathway more reassuring for our patients. And if we can translate our finding into clinical practice, then we will also save patients unnecessary side effects and reduce costs to the NHS."

"The immune system can play a powerful role in fighting lung cancer, and this research sheds more light on the interplay between cancer, our immune system, and immunotherapies,” said Justine Alford, senior science information officer at Cancer Research UK. “...research like this is crucial to understanding why some people with lung cancer respond well to treatment and, in future, could guide more personalized treatments for patients."

Additional source: Cancer Research UK

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
NOV 29, 2019
NOV 29, 2019
Protecting Killer Immune Cells from Themselves
Destroying human cells compromised by viruses and cancer is the name of the game for so-called “killer” cells of the immune system. They employ...
DEC 10, 2019
DEC 10, 2019
Using anthrax to fight cancer?
Surprising research published recently in the International Journal of Cancer says anthrax may act as a potential bladder cancer treatment. Yes, you read c...
DEC 16, 2019
Cell & Molecular Biology
DEC 16, 2019
When Migrating, Cancer Cells Choose the Path of Least Resistance
Cancer becomes most deadly when it has metastasized - when cancerous cells move away from the site where cancer started growing....
JAN 02, 2020
Drug Discovery & Development
JAN 02, 2020
FDA Approves Ovarian Cancer Drug to Treat Pancreatic Cancer
In 2019, an estimated 46,000 Americans died from pancreatic cancer. Now, the Food and Drug Administration (FDA) has approved Lynparza, an ovarian cancer dr...
FEB 04, 2020
FEB 04, 2020
The role of SRR in colorectal cancer
Researchers from Osaka University have recently discovered a new function of the multifunctional enzyme entitled serine racemase (SRR). According to the te...
FEB 19, 2020
Clinical & Molecular DX
FEB 19, 2020
Forget complicated scans - ovarian cancer can be detected in the blood
Results from clinical trials performed in Melbourne, Australia have revealed the diagnostic potential of a new test for ovarian cancer. Instead of using co...
Loading Comments...